Drugs for Separation Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 29)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
Dazolam
DB00683
Dea no. 2884
Dea No. 2884
DEA No. 2884
Dormicum
Dormicum (TN)
EINECS 261-774-5
|
Hydrochloride, midazolam
LS-77780
Maleate, midazolam
Midanium
midazolam
Midazolam
Midazolam (JAN/INN)
Midazolam [INN:BAN:JAN]
Midazolam base
Midazolam Base
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
nchembio747-comp32
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
|
|
2 |
|
Ketamine |
Approved, Vet_approved |
Phase 4 |
|
6740-88-1 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
3 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
4 |
|
Serotonin 5-HT1 Receptor Agonists |
|
Phase 4 |
|
|
|
5 |
|
Serotonin Receptor Agonists |
|
Phase 4 |
|
|
|
6 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
7 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
8 |
|
Vilazodone Hydrochloride |
|
Phase 4 |
|
163521-08-2 |
|
9 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
10 |
|
Anesthetics |
|
Phase 4 |
|
|
|
11 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
12 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
13 |
|
Anesthetics, Dissociative |
|
Phase 4 |
|
|
|
14 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
15 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
16 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
17 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
18 |
|
Analgesics |
|
Phase 4 |
|
|
|
19 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
20 |
|
Guanfacine |
Approved, Investigational |
Phase 2 |
|
29110-47-2 |
3519 |
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine
GUANFACINE
Guanfacine (INN)
Guanfacine [INN:BAN]
Guanfacine hydrochloride
Guanfacine monohydrochloride
Guanfacine Monohydrochloride
Guanfacinum
Guanfacinum [INN-Latin]
|
Hydrochloride, guanfacine
Intuniv
L000286
L013430
Lon798
Lopac0_000519
Lopac-G-1043
LS-174236
MolPort-003-941-447
Monohydrochloride, guanfacine
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tenex
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
|
|
21 |
|
Adrenergic alpha-Agonists |
|
Phase 2 |
|
|
|
22 |
|
Antihypertensive Agents |
|
Phase 2 |
|
|
|
23 |
|
Adrenergic Agents |
|
Phase 2 |
|
|
|
24 |
|
Adrenergic Agonists |
|
Phase 2 |
|
|
|
25 |
|
Citalopram |
Approved |
Phase 1 |
|
59729-33-8 |
2771 |
Synonyms:
[3H]Citalopram
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
Bonitrile
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
C07572
C20H21FN2O
Celapram
Celexa
Celius
CHEBI:3723
CHEMBL549
Ciazil
CID2771
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
citalopram
Citalopram
Citalopram (USP/INN)
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopram Hydrobromide
Citalopramum
Citalopramum [INN-Latin]
|
Citol
Citopam
Citox
Citrol
CPD000465669
Cytalopram
D07704
Dalsan
DB00215
EINECS 261-891-1
Elopram
Escitalopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
Lexapro
Lopac0_000258
LS-84327
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
Seropram
ST069372
STL058639
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
|
|
26 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
Phase 1 |
|
50-03-3 |
|
Synonyms:
21-O-acetylcortisol
Cortisol 21-acetate
|
Hydrocortisone 21-acetate
|
|
27 |
|
Hydrocortisone |
Approved, Vet_approved |
Phase 1 |
|
50-23-7 |
5754 |
Synonyms:
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
[3H]cortisol
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-hydrocortisone
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11β,17α,21-trihydroxy-4-pregnene-3,20-dione
11β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
2v95
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-pregnen-11β,17α,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
AI3-25006
AKOS001582651
Alacort
Ala-cort
Ala-Cort
Ala-scalp
Ala-Scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Anusol-HC
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
Balneol-hc
Balneol-HC
Barseb HC
Basan-corti
Basan-Corti
Beta-hc
Beta-HC
b-HC
Bio-0648
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
C00735
C21H30O5
CaldeCORT spray
CaldeCORT Spray
CCRIS 5854
Cetacort
CHEBI:17650
CHEMBL389621
Chronocort
CID5754
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
Compound F
Compound F (kendall)
Corhydron
Cor-oticin
COR-OTICIN
Cortanal
Cor-tar-quin
Cort-dome
Cort-Dome
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin otico
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
Cortril
CORTRIL
CPD000653523
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Dermacort
Derm-aid
Derm-Aid
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
Ef corlin
Efcorbin
Efcortelan
Efcortelin
EINECS 200-020-1
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EU-0100594
Evacort
Ficortril
Fiocortril
Flexicort
Foille insetti
Foille Insetti
Genacort
Genacort (lotion)
Glycort
gyno-Cortisone
Gyno-Cortisone
H 4001
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
|
H4001_SIGMA
H6909_SIGMA
HC
HC #1
HC #4
HC (HYDROCORTISONE)
H-Cort
Heb cort
Heb Cort
Heb-cort
Heb-Cort
Hi-cor
Hidalone
hidro-Colisona
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
HMS1569I16
HMS2090M04
HSDB 3339
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
Hydro-Adreson
hydro-Colisona
Hydro-Colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
hydrocortisone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone acetate
Hydrocortisone alcohol
HYDROCORTISONE AND ACETIC ACID
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
HYDROCORTISONE IN ABSORBASE
Hydrocortisone sodium phosphate
Hydrocortisone solution
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
HYDROCORTONE
hydro-RX
Hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
LMST02030001
Locoid
Lopac0_000594
LS-7439
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
Milliderm
MLS000069609
MLS001148103
MLS002207135
MLS002222189
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
neo-Cort-dome
neo-Cortef
Neo-Cortef
Neosporin-H ear
Neosporin-H Ear
Nogenic HC
NSC 10483
NSC10483
NSC-10483
Nutracort
Nystaform-HC
Ophthocort
Optef
ORLEX HC
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
Otosone-F
Pediotic suspension
Pediotic Suspension
Penecort
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Preparation H Hydrocortisone Cream
Prepcort
Prestwick_265
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein's substance m
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
Sanatison
Scalp-Cort
Scalpicin capilar
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Systral Hydrocort
Tarcortin
Terra-cortril
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
U-cort
Uniderm
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Vioform-hydrocortisone
VoSol HC
Vytone
Zenoxone
β-HC
|
|
28 |
|
Hydrocortisone 17-butyrate 21-propionate |
|
Phase 1 |
|
|
|
29 |
|
Hydrocortisone hemisuccinate |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 30)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Vilazodone for Separation Anxiety Disorder |
Completed |
NCT01999920 |
Phase 4 |
Vilazodone;Placebo |
2 |
Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders |
Completed |
NCT02579928 |
Phase 4 |
Ketamine;Midazolam |
3 |
A Randomized Controlled Trial of Multimodal Music Therapy for Children With Anxiety Disorders |
Completed |
NCT01062646 |
Phase 3 |
|
4 |
2/3 Treatment of Anxiety in Autism Spectrum Disorder |
Completed |
NCT02028247 |
Phase 3 |
|
5 |
Utilizing Health Information Technology to Improve Health Care Quality: Implementation of a Computerized Cognitive Behavioral Therapy Protocol for Childhood Anxiety |
Completed |
NCT01416805 |
Phase 3 |
|
6 |
Effectiveness of Group and Individual Treatment of Childhood Anxiety Disorders in Community Clinics. A Randomized Controlled Trial. |
Completed |
NCT00735995 |
Phase 2 |
|
7 |
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP). |
Completed |
NCT01470469 |
Phase 2 |
SPD503 (extended-release Guanfacine hydrochloride);Placebo |
8 |
A Randomized, Controlled Trial of Modular CBT for Child Anxiety Disorders in Elementary School Settings |
Completed |
NCT00569829 |
Phase 2 |
|
9 |
Assessment and Treatment - Anxiety in Children and Adults (Child Part) |
Completed |
NCT00586586 |
Phase 2 |
|
10 |
Effects of Parental Behavior on Child Anxiety Regulation |
Completed |
NCT00593515 |
Phase 2 |
|
11 |
A Brief Behavioral Treatment for Anxiety in Young Children |
Completed |
NCT02051192 |
Phase 1, Phase 2 |
|
12 |
Feasible Delivery of CBT for Rural Latino Youth With Anxiety |
Completed |
NCT01491880 |
Phase 1, Phase 2 |
|
13 |
Cipralex® for Anxiety Disorders in Adolescents: Clinical and Physiological Changes Associated With Open Label, Flexible-dose Treatment |
Unknown status |
NCT01293838 |
Phase 1 |
Cipralex® |
14 |
Effectiveness of Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and Anxiety |
Completed |
NCT01187784 |
Phase 1 |
|
15 |
Comorbidity Between Balance and Childhood Anxiety: Treatment of Anxiety by Training of Balance |
Unknown status |
NCT00599742 |
|
|
16 |
Investigating the Effects of an Added Parent Component to Cognitive Behavior Therapy for Youth With Anxiety Disorders |
Unknown status |
NCT02160444 |
|
|
17 |
Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children: a Randomized Clinical Trial |
Unknown status |
NCT01687764 |
|
|
18 |
Psychological Treatment of Separation Anxiety Disorder |
Completed |
NCT00255112 |
|
|
19 |
Internet-Based CBT for Children With Anxiety Disorders: Implementation in Clinical Settings |
Completed |
NCT02350257 |
|
|
20 |
Internet-delivered Cognitive Behavior Therapy (CBT) Treatment for Anxiety Disorders in Children Age 8-12 Years - a Randomised Controlled Trial |
Completed |
NCT01533402 |
|
|
21 |
Transdisciplinary Studies of CBT for Anxiety in Youth |
Completed |
NCT00774150 |
|
|
22 |
Sleep, Mood, and Behavior Study:Transdisciplinary Studies of CBT for Anxiety in Youth |
Completed |
NCT00787397 |
|
|
23 |
Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety |
Completed |
NCT01919970 |
|
|
24 |
Ventilatory Physiology in Children at Risk for Anxiety |
Completed |
NCT00101777 |
|
|
25 |
Early Interventions for Anxious Children |
Completed |
NCT00557648 |
|
|
26 |
Enhancing Specificity and Predictability of CBT Outcome for Pediatric Anxiety Disorders: A Pilot Test of a Potential Biomarker for Treatment Response Across Development |
Completed |
NCT03032926 |
|
|
27 |
Reward-Related Processes and Brain Function |
Completed |
NCT00029588 |
|
|
28 |
Psychotherapy Process and Outcomes in Cognitive-Behavioral Treatment for Anxious and Depressed Youth |
Recruiting |
NCT03100279 |
|
|
29 |
Attention Bias Modification Treatment for Anxious Youth |
Terminated |
NCT01979263 |
|
|
30 |
Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders: A Pilot Study |
Terminated |
NCT02572973 |
|
|
|